Evidence map›Paper›PMID 25604120›Full record

ArticleBMC medicine2014

Environmental enteropathy and malnutrition: do we know enough to intervene?

William A Petri, Caitlin Naylor, Rashidul Haque

Open access · goldAbstract readComment
In one paragraph

Article in BMC medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Nutritional Modulation of the Microbiome and Immune Response.Journal of immunology (Baltimore, Md. : 1950) · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

William A PetriDivision of Infectious Diseases & International Health, University of Virginia, Charlottesville, VA, 22908-1340, USA. wap3g@cms.mail.virginia.edu.
Caitlin NaylorDivision of Infectious Diseases & International Health, University of Virginia, Charlottesville, VA, 22908-1340, USA. cgn5q@virginia.edu.
Rashidul Haqueicddr,b, GPO Box 128, Mohakhali, Dhaka, 1000, Bangladesh. rhaque@icddrb.org.
University of Virginia · USInternational Centre for Diarrhoeal Disease Research · BD

Funding

INFECTIOUS DISEASES TRAINING PROGRAMT32AI007046 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Alison K Criss, William A Petri · 1985 to 2026
$15.3M
FIELD STUDIES OF IMMUNITY TO AMEBIASIS IN BANGLADESHR01AI043596 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI CAROL A GILCHRIST, William A Petri · 1998 to 2026
$7.7M
Global Biothreats Training ProgramT32AI055432 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI CRISS, ALISON K, PETRI, WILLIAM A · 2003 to 2022
$4.0M
NIAID NIH HHS 5R01AI043596-16NIAID NIH HHS R01 AI043596NIAID NIH HHS T32 AI007046NIAID NIH HHS T32 AI055432
6 · The paper itself

Abstract

Environmental enteropathy (EE) is a poorly defined state of intestinal inflammation without overt diarrhea that occurs in individuals exposed over time to poor sanitation and hygiene. It is implicated as a cause of stunting and malnutrition, oral vaccine failure and impaired development in children from low-income countries. The burden on child health of malnutrition alone, which affects 25% of all children and is estimated to result in more than a million deaths annually due to heightened susceptibility to infection, makes urgent a solution to EE. Efforts are thus underway to treat EE even while work continues to identify it through the use of non-invasive biomarkers, and delineate its pathogenesis. A recent study published in BMC Medicine reports the first randomized controlled phase I trial of an anti-inflammatory drug for EE. The aminosalicylate mesalazine was found to be safe in short-term treatment of a small number of severely malnourished children, although efficacy was not established. Whether such treatment trials are premature, or instead a way both to understand and intervene in EE, is the focus of this article. Please see related article: http://www.biomedcentral.com/1741-7015/12/133.

Indexed as

Inflammatory Bowel DiseasesAnti-Inflammatory Agents, Non-SteroidalFemaleHumansMaleMalnutritionMesalamineAnti-Inflammatory Agents, Non-SteroidalMesalamine

Identifiers

PMID25604120
PMCPMC4197320
OpenAlexW1974262141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.